Alpine Immune appoints Provention Bio exec new chief tech officer
Seattle, USA-based Alpine Immune Sciences (Nasdaq: ALPN), an immunotherapy company developing innovative treatments for autoimmune and inflammatory diseases, has named Christina Yi its new chief technology officer.
Ms Yi, who has more than 25 years of biopharmaceutical leadership experience across manufacturing, quality and supply chain functions, succeeds the retiring Wayne Gombotz.
"A key addition to our executive team as we prepare for a broad development plan for povetacicept"Mitchell Gold, the company’s executive chairman and chief executive, said: “Christina is an accomplished industry leader and will be a key addition to our executive team as we prepare for a broad development plan for povetacicept.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze